A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (NCT03466411)

🧪 Interventions in This Study

• Guselkumab Dose 1 (DRUG)
• Guselkumab Dose 2 (DRUG)
• Guselkumab Dose 3 (DRUG)
• Guselkumab Dose 4 (DRUG)
• Guselkumab Dose 5 (DRUG)
• Guselkumab (DRUG)
• Ustekinumab (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (579 Sites)

Showing the first 25 of 579 sites.

• Digestive Health Specialists of the Southeast — Dothan, Alabama
• Internal Medicine Center — Mobile, Alabama
• University of Arizona — Tucson, Arizona
• Advanced Research Center Inc — Anaheim, California
• Paul Wallace MD — Beverly Hills, California
• University Of California San Diego — La Jolla, California
• Om Research LLC — Lancaster, California
• Allameh Medical Corp — Mission Viejo, California
• United Gastroenterologists — Murrieta, California
• Clinnova Research — Orange, California
• Inland Empire Liver Foundation — Rialto, California
• UC Davis Medical Center — Sacramento, California
• Clinical Applications Laboratories, Inc — San Diego, California
• Peak Gastroenterology Associates — Colorado Springs, Colorado
• Pioneer Research Solutions Inc. — Coconut Creek, Florida
• InvesClinic, LLC — Fort Lauderdale, Florida
• Harmony Medical Research Institute, Inc. — Hialeah, Florida
• Elite Research Network - Nature Coast Clinical Research, LLC — Inverness, Florida
• SIH Research — Kissimmee, Florida
• Auzmer Research — Lakeland, Florida
• Florida Research Center Inc. — Lakewood Rch, Florida
• Homestead Associates in Research Inc — Miami, Florida
• Community Research Foundation, Inc. — Miami, Florida
• Sanchez Clinical Research, Inc — Miami, Florida
• Visionary Investigators Network — Miami, Florida

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Crohn's Disease

• A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) — Birmingham, Alabama
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Birmingham, Alabama
• A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. — Sun City, Arizona
• Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. — Blacktown, New South Wales
• Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients — San Francisco, California
• Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis — Boston, Massachusetts

Explore by condition: All Crohn's Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.